锡洛斯塔对耐火性血管位性心痛的影响
Richard Z Lin1,2,3, Rosanna Tavella4,5,6, Sepehr Shakib4
1Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia, richard.lin@adelaide.edu.au.
Cardiology
|February 27, 2025
概括
锡洛斯塔有效治疗耐火性血管性心痛 (VSA),改善患者报告的结果并减少医疗保健的使用. 这项现实研究表明,在VSA患者中,胸痛显著减少,耐受性良好.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 耐火性血管性心痛 (VSA) 呈现残疾症状,尽管标准治疗.
- 尽管有积极的试验证据,但对西洛斯塔在VSA中的疗效的现实数据有限.
- 这项研究调查了西洛斯塔对耐火性VSA患者报告结果的影响.
研究的目的:
- 为了评估基洛斯塔在治疗耐火性血管性心痛方面的有效性.
- 评估基洛斯塔对患者报告结果的影响,包括心痛频率,身体限制和生活质量.
- 为了确定在真实世界VSA患者队列中西洛斯塔的安全性和耐受性.
主要方法:
- 一项涉及15名耐火性VSA患者的前性研究开始于西洛斯塔 (50毫克每天两次).
- 患者的反应在基线和3个月后使用西雅图心脏病问卷 (SAQ) 进行评估.
- 主要结局是3个月后SAQ心痛频率得分的临床显著改善.
主要成果:
- 86%的患者实现了显著的胸痛频率降低,20%的患者变得无胸痛.
- 中位数SAQ得分在心痛频率,身体限制和生活质量方面显著改善.
- 观察到,急诊室访问减少了54%,心痛入院减少了50%. 奇洛斯塔佐尔耐受性很好,没有严重的不良事件.
结论:
- 在现实实践中,西洛斯塔是一种耐受性良好,有效的治疗方法,用于耐火性VSA患者.
- 该药物显著改善了患者报告的结果,并减少了医疗保健利用率.
- 锡洛斯塔为耐火性VSA患者提供了有价值的治疗选择.
相关概念视频
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
437
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
437
01:16Antianginal Drugs: Nitrates and β-Blockers
490
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
490
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
126
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
126
01:22Heart Failure Drugs: β-Blockers
306
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
306
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
142
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
142
01:23Antihypertensive Drugs: Vasodilators
455
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
455